From the floor of AAO 2025 in Orlando, Iantrek introduces AlloFlo™ Uveo, a breakthrough in glaucoma surgery that expands the surgeon’s reach beyond the trabecular meshwork.
Built on biotissue and designed for the uveoscleral pathway, AlloFlo™ Uveo brings a new dimension to minimally invasive glaucoma surgery that’s biointerventional, hardware-free and truly dual-pathway.
Featuring insights from Adam Szaronos and Dr. Sean Ianchulev, this video explores how AlloFlo™ Uveo meets the unmet need in post-MIGS eyes and ushers in a new era of patient-centered innovation.
See how Iantrek is redefining the future of outflow and giving glaucoma surgery a second act.
Learn more at https://iantrekmed.com.
This content is intended exclusively for healthcare professionals and eye care practitioners. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all jurisdictions, including Singapore.
